Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development

Ding, Qingjie, Zhang, Zhuming, Liu, Jin-Jun, Jiang, Nan, Zhang, Jing, Ross, Tina M., Chu, Xin-Jie, Bartkovitz, David +9 more·2013·Journal of Medicinal Chemistry
DOI 10.1021/jm400487c

Cited by (617)

Items 101–200 of 617

  1. Cyclic tailor-made amino acids in the design of modern pharmaceuticals
    Jiang Liu, Jianlin Han, Kunisuke Izawa, Tatsunori Sato, Sarah White, Nicholas A. Meanwell, Vadim A. Soloshonok · 2020 · European Journal of Medicinal Chemistry
  2. Enhanced Suppression of a Protein–Protein Interaction in Cells Using Small-Molecule Covalent Inhibitors Based on an N-Acyl-N-alkyl Sulfonamide Warhead
    Tsuyoshi Ueda, Tomonori Tamura, Masaharu Kawano, Keiya Shiono, Fruzsina Hóbor, Andrew John Wilson, Itaru Hamachi · 2021 · Journal of the American Chemical Society
  3. Selective and Potent Morpholinone Inhibitors of the MDM2–p53 Protein–Protein Interaction
    Ana Z. González, John E. Eksterowicz, Michael D. Bartberger, Hilary P. Beck, Jude R. Canon, Ada Chen, David T. Chow, Jason Duquette, Brian M. Fox, Jiasheng Fu et al. · 2014 · Journal of Medicinal Chemistry
  4. Medicinal Chemistry Strategies to Disrupt the p53–MDM2/MDMX Interaction
    Agostinho Lemos, Mariana Leão, Joana Soares, Andreia Palmeira, Madalena M. M. Pinto, Lucı́lia Saraiva, Maria Emília Sousa · 2016 · Medicinal Research Reviews
  5. Targeting the Ubiquitin-Proteasome System for Cancer Therapeutics by Small-Molecule Inhibitors
    Gabriel LaPlante, Wei Zhang · 2021 · Cancers
  6. Pharmacological reactivation of p53 as a strategy to treat cancer
    Zawacka‐Pankau, J., Selivanova, G. · 2015 · Journal of Internal Medicine
  7. Toward Small-Molecule Inhibition of Protein–Protein Interactions: General Aspects and Recent Progress in Targeting Costimulatory and Coinhibitory (Immune Checkpoint) Interactions
    Damir Bojadzic, Péter Buchwald · 2018 · Current Topics in Medicinal Chemistry
  8. Design and synthesis of new substituted spirooxindoles as potential inhibitors of the MDM2–p53 interaction
    Assem Barakat, Mohammad Shahidul Islam, Hussien Mansur Ghawas, Abdullah Mohammed Al‐Majid, Fardous F. El‐Senduny, Farid Abd-Elreheim Badria, Yaseen A. M. M. Elshaier, Hazem A. Ghabbour · 2019 · Bioorganic Chemistry
  9. Reviving the guardian of the genome: Small molecule activators of p53
    Daniel Nguyen, Wenjuan Liao, Shelya X. Zeng, Hua Lu · 2017 · Pharmacology & Therapeutics
  10. Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma
    Lindi Chen, Raphaël F. Rousseau, Steven A. Middleton, GWEN L. NICHOLS, David R. Newell, John Lunec, Deborah A. Tweddle · 2015 · Oncotarget
  11. Therapeutic Approaches Targeting Nucleolus in Cancer
    Pietro Carotenuto, Annalisa Pecoraro, Gaetano Palma, Giulia Russo, Annapina Russo · 2019 · Cells
  12. Design of Chemically Stable, Potent, and Efficacious MDM2 Inhibitors That Exploit the Retro-Mannich Ring-Opening-Cyclization Reaction Mechanism in Spiro-oxindoles
    Angelo Aguilar, Wei Sun, Liu Liu, Jianfeng Lu, Donna McEachern, Denzil Bernard, Jeffrey R. Deschamps, Shaomeng Wang · 2014 · Journal of Medicinal Chemistry
  13. Current advances in temozolomide encapsulation for the enhancement of glioblastoma treatment
    Nerea Iturrioz-Rodríguez, Nicolàs Samprón, Ander Matheu · 2023 · Theranostics
  14. The MDM2 small-molecule inhibitor RG7388 leads to potent tumor inhibition in p53 wild-type neuroblastoma
    Anna Lakoma, Eveline Barbieri, Saurabh Agarwal, Jeremy R. Jackson, Z Chen, Y Kim, Matthew C. McVay, Jason Matthew Shohet, Eugene S. Kim · 2015 · Cell Death Discovery
  15. MIRROS: A Randomized, Placebo-Controlled, Phase III Trial of Cytarabine ± Idasanutlin in Relapsed or Refractory Acute Myeloid Leukemia
    Pau Montesinos, Benjamin M. Beckermann, Olivier Catalani, Jordi Esteve, Katia Gamel, Marina Y Konopleva, Giovanni Martinelli, Annabelle Monnet, Cristina Papayannidis, Aaron Park et al. · 2020 · Future Oncology
  16. BRD4-mediated repression of p53 is a target for combination therapy in AML
    Anne‐Louise Latif, Ashley Newcombe, Sha Li, Kathryn L. Gilroy, Neil Robertson, Xue Lei, Stewart Helen, John J Cole, Maria Terradas-Terradas, Loveena Rishi et al. · 2021 · Nature Communications
  17. Prolonged Idasanutlin (RG7388) Treatment Leads to the Generation of p53-Mutated Cells
    Łukasz Skalniak, Justyna Kocik-Krol, Justyna Polak, Anna Skalniak, Monika Rak, Agnieszka Wolnicka-Głubisz, Tad A. Holak · 2018 · Cancers
  18. Targeting Resistance against the MDM2 Inhibitor RG7388 in Glioblastoma Cells by the MEK Inhibitor Trametinib
    Berberich, Anne, Kessler, Tobias, Thomé, Carina M., Pusch, Stefan, Hielscher, Thomas, Sahm, Felix, Oezen, Iris, Schmitt, Lara-Marie, Ciprut, Sara, Hucke, Nanina et al. · 2019 · Clinical Cancer Research
  19. Differential Mechanisms of Cell Death Induced by HDAC Inhibitor SAHA and MDM2 Inhibitor RG7388 in MCF-7 Cells
    Umamaheswari Natarajan, Thiagarajan Venkatesan, Vijayaraghavan Radhakrishnan, Shila Samuel, Appu Rathinavelu · 2018 · Cells
  20. Inhibition of WIP1 phosphatase sensitizes breast cancer cells to genotoxic stress and to MDM2 antagonist nutlin-3
    Soňa Pecháčková, Kamila Burdová, Jan Benada, Petra Kleiblová, Gabriela Jeníková, Libor Macůrek · 2016 · Oncotarget
  21. RB, p130 and p107 differentially repress G1/S and G2/M genes after p53 activation
    Amy E. Schade, Martin Fischer, James A. DeCaprio · 2019 · Nucleic Acids Research
  22. First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models
    Pairawan, Seyed, Zhao, Ming, Yuca, Erkan, Annis, Allen, Evans, Kurt, Sutton, David, Carvajal, Luis, Ren, Jian-Guo, Santiago, Solimar, Guerlavais, Vincent et al. · 2021 · Breast Cancer Research
  23. Current strategies and progress for targeting the “undruggable” transcription factors
    Jingjing Zhuang, Qian Liu, Dalei Wu, Lu Tie · 2022 · Acta Pharmacologica Sinica
  24. Structural analysis of MDM2 RING separates degradation from regulation of p53 transcription activity
    Koji Nomura, Marta Klejnot, Dominika Kowalczyk, Andreas K Hock, Gary J Sibbet, Karen H. Vousden, Danny T. C. Huang · 2017 · Nature Structural & Molecular Biology
  25. Small molecules targeting protein–protein interactions for cancer therapy
    Wu, Defa, Li, Yang, Zheng, Lang, Xiao, Huan, Ouyang, Liang, Wang, Guan, Sun, Qiu · 2023 · Acta Pharmaceutica Sinica B
  26. TP53 Mutations in Acute Myeloid Leukemia: Still a Daunting Challenge?
    Matteo Molica, Carla Mazzone, Pasquale Niscola, Paolo de Fabritiis · 2021 · Frontiers in Oncology
  27. Resistance mechanisms to inhibitors of p53-MDM2 interactions in cancer therapy: can we overcome them?
    Lucia Hároníková, Ondřej Bonczek, Pavlína Zatloukalová, Filip Zavadil Kokas, Martina Kucerikova, Philip John Coates, Robin Fåhræus, Bořivoj Vojtěšek · 2021 · Cellular & Molecular Biology Letters
  28. Advanced Strategies for Therapeutic Targeting of Wild-Type and Mutant p53 in Cancer
    Shengliang Zhang, Lindsey Carlsen, Liz J. Hernández Borrero, Attila A. Seyhan, Xiaobing Tian, Wafik S. El‐Deiry · 2022 · Biomolecules
  29. MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors
    Thomas P. Howard, Taylor E. Arnoff, Melinda R. Song, Andrew O. Giacomelli, Xiaofeng Wang, Andrew Lee Hong, Neekesh V. Dharia, Su Wang, Francisca Vázquez, Minh‐Tam Pham et al. · 2019 · Cancer Research
  30. Potent effect of the MDM2 inhibitor AMG232 on suppression of glioblastoma stem cells
    Her, Nam-Gu, Oh, Jeong-Woo, Oh, Yun Jeong, Han, Suji, Cho, Hee Jin, Lee, Yeri, Ryu, Gyu Ha, Nam, Do-Hyun · 2018 · Cell Death & Disease
  31. Idasanutlin Plus Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia: Results of the MIRROS Trial
    Marina Y Konopleva, Christoph Röllig, Jamie D. Cavenagh, Dries Deeren, Larisa Girshova, Jürgen Krauter, Giovanni Martinelli, Pau Montesinos, Jonas Schäfer, Oliver Gerhard Ottmann et al. · 2022 · Blood Advances
  32. Development of MDM2 degraders based on ligands derived from Ugi reactions: Lessons and discoveries
    Wang, Bo, Liu, Jin, Tandon, Ira, Wu, Suzhen, Teng, Peng, Liao, Jianhua, Tang, Weiping · 2021 · European Journal of Medicinal Chemistry
  33. PROTAC degraders with ligands recruiting MDM2 E3 ubiquitin ligase: an updated perspective
    Xin Han, Wenyi Wei, Yi Sun · 2022 · Acta Materia Medica
  34. PROTACs: A novel strategy for cancer drug discovery and development
    Xin Han, Yi Sun · 2023 · MedComm
  35. The role of ubiquitination in health and disease
    Yan Liao, Wangzheqi Zhang, Yang Liu, Cheng‐long Zhu, Zui Zou · 2024 · MedComm
  36. Synthesis and evaluation of spiroisoxazoline oxindoles as anticancer agents
    Carlos J. A. Ribeiro, Joana D. Amaral, Cecília M. P. Rodrigues, Rui Moreira, Maria M. M. Santos · 2013 · Bioorganic & Medicinal Chemistry
  37. Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in TP53 wild-type Ewing sarcoma
    Björn Stolte, Amanda Balboni Iniguez, Neekesh V. Dharia, Amanda L. Robichaud, Amy Saur Conway, Ann M. Morgan, Gabriela Alexe, Nathan J. Schauer, Xiaoxi Liu, Gregory H. Bird et al. · 2018 · The Journal of Experimental Medicine
  38. Targeting the p53 signaling pathway in cancers: Molecular mechanisms and clinical studies
    Jinze Shen, Qurui Wang, Yunan Mao, Wei Gao, Shiwei Duan · 2023 · MedComm
  39. Role of p53 circuitry in tumorigenesis: A brief review
    Niazi, Sarfaraj, Purohit, Madhusudan, Niazi, Javed H. · 2018 · European Journal of Medicinal Chemistry
  40. Wild type p53 reactivation: From lab bench to clinic
    Galina Selivanova · 2014 · FEBS Letters
  41. Preclinical Optimization of MDM2 Antagonist Scheduling for Cancer Treatment by Using a Model-Based Approach
    Higgins, Brian, Glenn, Kelli, Walz, Antje, Tovar, Christian, Filipovic, Zoran, Hussain, Sazzad, Lee, Edmund, Kolinsky, Kenneth, Tannu, Shahid, Adames, Violeta et al. · 2014 · Clinical Cancer Research
  42. The development of piperidinones as potent MDM2-P53 protein-protein interaction inhibitors for cancer therapy
    Liao, Guochao, Yang, Deying, Ma, Leilei, Li, Wenwei, Hu, Liqin, Zeng, Liming, Wu, Peng, Duan, Lixin, Liu, Zhongqiu · 2018 · European Journal of Medicinal Chemistry
  43. The role of the MDM2/p53 axis in antitumor immune responses
    Tilman Brummer, Robert Zeiser · 2023 · Blood
  44. Computational approaches for the design of modulators targeting protein-protein interactions
    Ashfaq Ur Rehman, Beenish Khurshid, Yasir Ali, Salman Rasheed, Abdul Wadood, Ho Leung Ng, Haifeng Chen, Zhiqiang Wei, Ray Luo, Jian Zhang · 2023 · Expert Opinion on Drug Discovery
  45. Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer
    Maryam Zanjirband, Richard John Edmondson, John Lunec · 2016 · Oncotarget
  46. Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma
    Chiao‐En Wu, Arman Esfandiari, Yi-Hsuan Ho, Nan Wang, Ahmed Khairallah Mahdi, Erhan Aptullahoğlu, Penny E. Lovat, John Lunec · 2017 · British Journal of Cancer
  47. Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy
    Zhang, Zhuming, Ding, Qingjie, Liu, Jin-Jun, Zhang, Jing, Jiang, Nan, Chu, Xin-Jie, Bartkovitz, David, Luk, Kin-Chun, Janson, Cheryl, Tovar, Christian et al. · 2014 · Bioorganic & Medicinal Chemistry
  48. Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal Microenvironment
    Hui Qin Wang, Iain J. Mulford, Fiona A. Sharp, Jinsheng Liang, Sema Kurtuluş, Gina M. Trabucco, David S. Quinn, Tyler A. Longmire, Nidhi Patel, Roshani A. Patil et al. · 2021 · Cancer Research
  49. Design and synthesis of new bioisosteres of spirooxindoles (MI-63/219) as anti-breast cancer agents
    Atul Kumar, Garima Gupta, Ajay Kumar Bishnoi, Ruchi Saxena, Karan Singh Saini, Rituraj Konwar, Sandeep Kumar, Anila Dwivedi · 2014 · Bioorganic & Medicinal Chemistry
  50. Precision Oncology, Signaling, and Anticancer Agents in Cancer Therapeutics
    Dia Advani, Sudhanshu Sharma, Smita Kumari, Rashmi K. Ambasta, Pravir Kumar · 2021 · Anti-Cancer Agents in Medicinal Chemistry
  51. Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition
    Jo Ishizawa, Kenji Nakamaru, Takahiko Seki, Koichi Tazaki, Kensuke Kojima, Dhruv Chachad, Ran Zhao, Lauren E. Heese, Wencai Ma, Man Chun John Ma et al. · 2018 · Cancer Research
  52. p53‐mediated adaptation to serine starvation is retained by a common tumour‐derived mutant
    Humpton, Timothy J., Hock, Andreas K., Maddocks, Oliver D. K., Vousden, Karen H. · 2018 · Cancer & Metabolism
  53. Novel Inhibitors of the MDM2-p53 Interaction Featuring Hydrogen Bond Acceptors as Carboxylic Acid Isosteres
    Ana Z. González, Zhihong Li, Hilary P. Beck, Jude R. Canon, Ada Chen, David T. Chow, Jason Duquette, John E. Eksterowicz, Brian M. Fox, Jiasheng Fu et al. · 2014 · Journal of Medicinal Chemistry
  54. Small-Molecule MDM2-p53 Inhibitors: Recent Advances
    Bian Zhang, Bernard T. Golding, Ian Robert Hardcastle · 2015 · Future Medicinal Chemistry
  55. Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein–Protein Interaction
    Gianni Chessari, Ian Robert Hardcastle, Jong Sook Ahn, Burcu Anil, Elizabeth Anscombe, Ruth H. Bawn, Luke Bevan, Timothy J. Blackburn, Ildiko M. Buck, Céline Cano et al. · 2021 · Journal of Medicinal Chemistry
  56. Ubiquitin–proteasome system as a target for anticancer treatment—an update
    Yeon Jung Kim, Yeonjoo Lee, H. Y. Shin, SuA Hwang, Jin‐Young Park, Eun Joo Song · 2023 · Archives of Pharmacal Research
  57. Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097
    Weisberg, Ellen, Halilovic, Ensar, Cooke, Vesselina G., Nonami, Atsushi, Ren, Tao, Sanda, Takaomi, Simkin, Irene, Yuan, Jing, Antonakos, Brandon, Barys, Louise et al. · 2015 · Molecular Cancer Therapeutics
  58. Transient Protein States in Designing Inhibitors of the MDM2-p53 Interaction
    Michał Biśta, Siglinde Wolf, Kareem Khoury, Kaja Kowalska, Yijun Huang, Ewa Wrona, Marcelino Arciniega, Grzegorz M. Popowicz, Tad A. Holak, Alexander S. S. Dömling · 2013 · Structure
  59. WIP1 phosphatase as pharmacological target in cancer therapy
    Soňa Pecháčková, Kamila Burdová, Libor Macůrek · 2017 · Journal of Molecular Medicine
  60. When the guardian sleeps: Reactivation of the p53 pathway in cancer
    Olaf Merkel, Ninon Taylor, Nicole Prutsch, Philipp Bernhard Staber, Richard Moriggl, Suzanne Dawn Turner, Lukas Kenner · 2017 · Mutation Research/Reviews in Mutation Research
  61. P53 activation inhibits all types of hematopoietic progenitors and all stages of megakaryopoiesis
    Mahfoudhi, Emna, Lordier, Larissa, Marty, Caroline, Pan, Jiajia, Roy, Anita, Roy, Lydia, Rameau, Philippe, Abbes, Salem, Debili, Najet, Raslova, Hana et al. · 2016 · Oncotarget
  62. MDM2-Based Proteolysis-Targeting Chimeras (PROTACs): An Innovative Drug Strategy for Cancer Treatment
    André T. S. Vicente, Jorge A. R. Salvador · 2022 · International Journal of Molecular Sciences
  63. Regio- and stereoselective synthesis of new spirooxindoles via 1,3-dipolar cycloaddition reaction: Anticancer and molecular docking studies
    Gehad Lotfy, El Sayed H. El Ashry, Mohamed M. Said, El Sayed El Tamany, Yasmine M. Abdel Aziz, Abdullah Al‐Dhfyan, Abdullah Mohammed Al‐Majid, Assem Barakat · 2018 · Journal of Photochemistry and Photobiology B Biology
  64. De novo molecular design with deep molecular generative models for PPI inhibitors
    Jianmin Wang, Yanyi Chu, Jiashun Mao, Hyeon-Nae Jeon, Haiyan Jin, Amir Zeb, Yuil Jang, Kwang‐Hwi Cho, Tao Song, Kyoung Tai No · 2022 · Briefings in Bioinformatics
  65. Pharmacological activation of wild-type p53 in the therapy of leukemia
    Kensuke Kojima, Jo Ishizawa, Michael Andreeff · 2016 · Experimental Hematology
  66. Precision medicine in nasopharyngeal carcinoma: comprehensive review of past, present, and future prospect
    Pui Yan Siak, Win Sen Heng, Sharon Siew Hoon Teoh, Yu Yu Lwin, Shiau‐Chuen Cheah · 2023 · Journal of Translational Medicine
  67. Development of CD133 Targeting Multi-Drug Polymer Micellar Nanoparticles for Glioblastoma - In Vitro Evaluation in Glioblastoma Stem Cells
    Shelby B. Smiley, Yeonhee Yun, Pranav Ayyagari, Harlan E. Shannon, Karen E. Pollok, Michael Walter Vannier, SUDIP KUMAR DAS, Michael C. Veronesi · 2021 · Pharmaceutical Research
  68. Organocatalytic, Diastereo- and Enantioselective Synthesis of Nonsymmetric cis -Stilbene Diamines: A Platform for the Preparation of Single-Enantiomer cis -Imidazolines for Protein–Protein Inhibition
    Brandon Vara, Anand Mayasundari, John C. Tellis, Michael W. Danneman, Vanessa Arredondo, Tyler A. Davis, Jaeki Min, Kristin E. Finch, Rodney Kiplin Guy, Jeffrey N. Johnston · 2014 · The Journal of Organic Chemistry
  69. TP53 in Acute Myeloid Leukemia: Molecular Aspects and Patterns of Mutation
    Binsah George, Hagop M. Kantarjian, Natalia Baran, Joseph D. Krocker, Adan A. Rios · 2021 · International Journal of Molecular Sciences
  70. Combination therapy in a xenograft model of glioblastoma: Enhancement of the antitumor activity of temozolomide by an MDM2 antagonist
    Wang, Haiyan, Cai, Shanbao, Bailey, Barbara J., Reza Saadatzadeh, M., Ding, Jixin, Tonsing-Carter, Eva, Georgiadis, Taxiarchis M., Zachary Gunter, T., Long, Eric C., Minto, Robert E. et al. · 2017 · Journal of Neurosurgery
  71. Regulation of p53 stability as a therapeutic strategy for cancer
    Zhifei Xu, Wentong Wu, Hao Yan, Yuhuai Hu, Qiaojun He, Peihua Luo · 2021 · Biochemical Pharmacology
  72. Saturated Heterocycles with Applications in Medicinal Chemistry
    Charles M. Marson · 2016 · Advances in heterocyclic chemistry
  73. Photoactivation of MDM2 Inhibitors: Controlling Protein–Protein Interaction with Light
    Mickel J. Hansen, Femke M. Feringa, Piermichele Kobauri, Wiktor Szymański, René H. Medema, Ben L. Feringa · 2018 · Journal of the American Chemical Society
  74. An integrated in silico screening strategy for identifying promising disruptors of p53-MDM2 interaction
    Hajar Sirous, Giulia Chemi, Giuseppe Campiani, Simone Brogi · 2019 · Computational Biology and Chemistry
  75. Recent Advances in Cancer Therapeutics
    Nicola E. A. Chessum, Keith Jones, Elisa Pasqua, Michael Tucker · 2015 · Progress in medicinal chemistry
  76. Pharmacologic activation of wild-type p53 by nutlin therapy in childhood cancer
    Tom Van Maerken, Ali Rihani, Alan Van Goethem, Anne De Paepe, Frank Speleman, Jo Vandesompele · 2013 · Cancer Letters
  77. Recent Progress and Clinical Development of Inhibitors that Block MDM4/p53 Protein–Protein Interactions
    Shiyan Zhang, Jianfeng Lou, Yafang Li, Feilong Zhou, Ziqin Yan, Xilin Lyu, Yujun Zhao · 2021 · Journal of Medicinal Chemistry
  78. Helping the released guardian: Drug combinations for supporting the anticancer activity of HDM2 (MDM2) antagonists
    Kocik, Justyna, Machula, Monika, Wisniewska, Aneta, Surmiak, Ewa, Holak, Tad A., Skalniak, Lukasz · 2019 · Cancers
  79. Catalytic Enantioselective [3+2] Cycloaddition of N‐Metalated Azomethine Ylides
    Sundaravel Vivek Kumar, Patrick J. Guiry · 2023 · Chemistry - A European Journal
  80. Targeting RING domains of Mdm2–MdmX E3 complex activates apoptotic arm of the p53 pathway in leukemia/lymphoma cells
    Wenjie Wu, Chao Xu, Xing Ling, Chuandong Fan, Brian Buckley, Mikhail V. Chernov, Leigh Ellis, F Li, Inés G. Muñoz, Xinjiang Wang · 2015 · Cell Death and Disease
  81. Small molecule activators of the p53 response
    Marcus J.G.W. Ladds, Sonia Laı́n · 2019 · Journal of Molecular Cell Biology
  82. A balancing act: using small molecules for therapeutic intervention of the p53 pathway in cancer
    Jessica J. Miller, Christian Gaiddon, Tim Storr · 2020 · Chemical Society Reviews
  83. Potential Therapeutic Targets in Uterine Sarcomas
    Tine Cuppens, Sandra Tuyaerts, Frédéric C. Amant · 2015 · Sarcoma
  84. Discovery of AM-7209, a Potent and Selective 4-Amidobenzoic Acid Inhibitor of the MDM2–p53 Interaction
    Yosup Rew, Daqing Sun, Xuelei Yan, Hilary P. Beck, Jude R. Canon, Ada Chen, Jason Duquette, John E. Eksterowicz, Brian M. Fox, Jiasheng Fu et al. · 2014 · Journal of Medicinal Chemistry
  85. A therapeutic patent overview of MDM2/X-targeted therapies (2014–2018)
    Łukasz Skalniak, Ewa Surmiak, Tad A. Holak · 2019 · Expert Opinion on Therapeutic Patents
  86. Targeting Apoptosis in Acute Myeloid Leukemia: Current Status and Future Directions of BCL-2 Inhibition with Venetoclax and Beyond
    Jun‐Hui Choi, James M. Bogenberger, Raoul Tibes · 2020 · Targeted Oncology
  87. Therapeutic potential of p53 reactivation in prostate cancer: Strategies and opportunities
    Sangeeta Kumari, Vikas Sharma, Rahul Tiwari, Jay Prakash Maurya, Bharat Bhusan Subudhi, Dhirodatta Senapati · 2022 · European Journal of Pharmacology
  88. Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non–Small Cell Lung Cancer Xenograft Models
    Josephine Hai, Shingo Sakashita, Ghassan Allo, Olga Ludkovski, Christine Ng, Frances A. Shepherd, Ming‐Sound Tsao · 2015 · Journal of Thoracic Oncology
  89. Drugging the ‘undruggable’. Therapeutic targeting of protein–DNA interactions with the use of computer-aided drug discovery methods
    Mariia Radaeva, Anh‐Tien Ton, Michael Hsing, Fuqiang Ban, Artem R Cherkasov · 2021 · Drug Discovery Today
  90. Structurally diverse MDM2–p53 antagonists act as modulators of MDR-1 function in neuroblastoma
    L Chen, Yan Zhao, Gail C. Halliday, P. Berry, Raphaël F. Rousseau, S A Middleton, GWEN L. NICHOLS, Fabio Del Bello, Alessia Piergentili, David R. Newell et al. · 2014 · British Journal of Cancer
  91. The Role of MDM2 in Promoting Genome Stability versus Instability
    Mohammad Reza Saadatzadeh, Adily N. Elmi, Pankita H. Pandya, Khadijeh Bijangi‐Vishehsaraei, Jixin Ding, Christopher W. Stamatkin, Aaron Cohen‐Gadol, Karen E. Pollok · 2017 · International Journal of Molecular Sciences
  92. Cell‐ and Tissue‐Based Proteome Profiling and Dual Imaging of Apoptosis Markers with Probes Derived from Venetoclax and Idasanutlin
    Dongsheng Zhu, Haijun Guo, Yu Chang, Yun Ni, Lin Li, Zhi‐Min Zhang, Piliang Hao, Yong Xu, Ke Ding, Zhengqiu Li · 2018 · Angewandte Chemie International Edition
  93. Writing Histone Monoubiquitination in Human Malignancy—The Role of RING Finger E3 Ubiquitin Ligases
    Deborah J. Marsh, Kristie-Ann Dickson · 2019 · Genes
  94. MDM4 inhibition: a novel therapeutic strategy to reactivate p53 in hepatoblastoma
    Sarah E. Woodfield, Yan Ping Shi, Roma H. Patel, Zhenghu Chen, Aayushi P. Shah, Rohit Kumar Srivastava, Richard S. Whitlock, Aryana M. Ibarra, Samuel R. Larson, Stephen Frederick Sarabia et al. · 2021 · Scientific Reports
  95. Computational Modeling as a Tool to Investigate PPI: From Drug Design to Tissue Engineering
    Juan Jesús Pérez, Román A. Pérez, Alberto Pérez · 2021 · Frontiers in Molecular Biosciences
  96. Small‐Molecule Inhibitors That Target Protein–Protein Interactions in the RAD51 Family of Recombinases
    Duncan E. Scott, Anthony G. Coyne, Ashok R. Venkitaraman, Tom L. Blundell, Chris Abell, Marko Hyvönen · 2014 · ChemMedChem
  97. Discovery of DS-5272 as a promising candidate: A potent and orally active p53–MDM2 interaction inhibitor
    Masaki Miyazaki, Kouichi Uoto, Yuuichi Sugimoto, Hiroyuki Naito, Keisuke Yoshida, Tooru Okayama, Haruko C. Kawato, Masaya Miyazaki, Mayumi Kitagawa, Takahiko Seki et al. · 2015 · Bioorganic & Medicinal Chemistry
  98. Novel, Selective Inhibitors of USP7 Uncover Multiple Mechanisms of Antitumor Activity In Vitro and In Vivo
    Yamini M. Ohol, Michael T. Sun, Gene Cutler, Paul R. Leger, Dennis X. Hu, Bérenger Biannic, Payal Rana, Cynthia Cho, Scott Jacobson, Steve Wong et al. · 2020 · Molecular Cancer Therapeutics
  99. MDM2/X inhibitors as radiosensitizers for glioblastoma targeted therapy
    Miles, Xanthene, Vandevoorde, Charlot, Hunter, Alistair, Bolcaen, Julie · 2021 · Frontiers in Oncology
  100. Metabolic Roles of HIF1, c-Myc, and p53 in Glioma Cells
    Cristina Trejo‐Solís, Rosa Angélica Castillo‐Rodríguez, Norma Serrano-García, Daniela Silva‐Adaya, Salvador Vargas-Cruz, Elda Georgina Chávez-Cortéz, Juan Carlos Gallardo‐Pérez, Sergio Zavala-Vega, Arturo Cruz-Salgado, Roxana Magaña-Maldonado · 2024 · Metabolites